# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Emily Dickinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI023-SYN
- Date: 2026-01-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucinda Hartwell, MD
- Calendar frame: modern shifted

## What we are working on

- Headaches, nausea, and tiredness for several months, worse in the mornings **S**
- Wants her care at home or by video, with as few trips to the clinic as possible **S**

## Your goals

- Systolic blood pressure below 120 mmHg (KDIGO), and at least below 130/80, without lightheadedness. Target: 2026-09-28. Recorded outcome: 118/74 mmHg on losartan 100 mg and amlodipine 5 mg. **S**
- Urine albumin-creatinine ratio down by at least 30 percent from baseline on an ARB and an SGLT2 inhibitor. Target: 2026-06-01. Recorded outcome: 118 mg/g at three months and 96 mg/g at six months, from 240 mg/g. **S**
- Stable kidney function, with no fall in eGFR of more than 20 percent after the expected early dip. Target: 2026-09-28. Recorded outcome: eGFR 50 at the six-month review (54 at baseline); a temporary fall to 36 during gastroenteritis recovered. **S**
- 25-hydroxyvitamin D of at least 30 ng/mL. Target: 2026-09-28. Recorded outcome: 36 ng/mL on vitamin D3; PTH 61 pg/mL. **S**
- Care delivered at home or by video wherever safe, with clinic trips limited to tests that need the clinic. Target: 2026-09-28. Recorded outcome: Two clinic trips in the episode, each combining several tasks; all other visits at home or by video. **S**

## What we agreed to do

- Start losartan 50 mg daily and raise it to the maximum dose of 100 mg for A2 albuminuria; check potassium and creatinine 2 to 4 weeks after each start or increase, accepting a creatinine rise of up to 30 percent. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- If a second sample confirms a urine albumin-creatinine ratio of at least 200 mg/g, add an SGLT2 inhibitor (dapagliflozin 10 mg daily) after the nephrology review, and check potassium and creatinine 2 to 4 weeks later. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- Stop naproxen and avoid all NSAIDs; acetaminophen for headache; check kidney function before any iodinated contrast; adjust drug doses to eGFR. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- Nephrology consultation to confirm the cause of chronic kidney disease with albuminuria in a woman in her fifties and to advise on treatment and follow-up. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- Sick-day guidance: during vomiting, diarrhea, or poor fluid intake, pause losartan, dapagliflozin, and any other blood pressure medicine, drink fluids, call the clinic, and restart after 24 to 48 hours of normal eating and drinking. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- CMID kidney and blood pressure monitoring: blood pressure every visit with home readings; eGFR and urine albumin twice a year at G3a A2; a metabolic panel with each draw; calcium, phosphate, and PTH every 6 to 12 months; vitamin D at baseline; hemoglobin and KFRE yearly; one lipid panel and a statin; medication review every visit; vaccines reviewed yearly. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- Atorvastatin 20 mg daily; vitamin D3 1,000 units daily with recheck of 25-hydroxyvitamin D, calcium, phosphate, and PTH. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- Vaccines for chronic kidney disease: PCV20 now, a two-dose hepatitis B series, and yearly influenza and COVID-19 vaccines. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026); Adult Immunization Schedule by Age (2026) **S**
- Home-centered care: home visits and video visits with her own validated blood pressure cuff, scale, thermometer, and pulse oximeter; mobile phlebotomy; clinic trips only for tests that need them, with several tasks booked on one quiet early appointment. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- PHQ-9 and GAD-7 at baseline and yearly; her long-standing wish for solitude is respected and not treated as a disorder unless symptoms cause distress or impairment. Guideline: CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026); Anxiety Disorders in Adults: Screening (2023); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Sodium below 2 g a day, a plant-rich diet, and at least 150 minutes a week of activity, such as garden work and walking. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**

## Follow-up

- 2026-01-12: Primary care home visit for headaches, nausea, and tiredness, with raised blood pressure and abnormal kidney tests **S**
- 2026-02-02: Three-week kidney and blood pressure review in the clinic, combined with nephrology consultation and kidney ultrasound on one trip **S**
- 2026-03-02: Video visit four weeks after the losartan increase and dapagliflozin start, with home vital signs and home blood tests **S**
- 2026-06-01: Home visit for the three-month kidney and blood pressure review **S**
- 2026-09-28: Video visit for the six-month kidney review, with home vital signs and home blood tests **S**
- 2026-10-19: Periodic adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
